MARKET

ACAD

ACAD

ACADIA Pharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

46.10
+0.63
+1.39%
After Hours: 46.11 +0.01 +0.02% 19:15 11/15 EST
OPEN
45.87
PREV CLOSE
45.47
HIGH
47.05
LOW
45.77
VOLUME
1.34M
TURNOVER
--
52 WEEK HIGH
47.79
52 WEEK LOW
14.01
MARKET CAP
7.08B
P/E (TTM)
-26.2200
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ACAD and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ACAD News

  • The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher
  • Benzinga.3d ago
  • The Zacks Analyst Blog Highlights: Coherus, Incyte, ACADIA and Celgene
  • Zacks.4d ago
  • The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat
  • Benzinga.4d ago
  • IBD Stock Of The Day Breaks Out As It Stares Down A Massive Opportunity
  • Investor's Business Daily.5d ago

More

Industry

Biotechnology & Medical Research
+1.25%
Pharmaceuticals & Medical Research
+1.34%

Hot Stocks

Name
Price
%Change

About ACAD

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PD Psychosis). NUPLAZID is a selective serotonin inverse agonist (SSIA), preferentially targeting 5-HT2A receptors. The Company is conducting a Phase II trial, referred to as the SERENE Study, designed to examine the efficacy and safety of pimavanserin as a treatment for Alzheimer's disease (AD) Agitation. It is also conducting a Phase III, six-week, randomized, double-blind, placebo-controlled, multi-center, outpatient study, referred to as the ENHANCE-1 study, designed to examine the use of pimavanserin in patients with schizophrenia.
More

Webull offers ACADIA Pharmaceuticals Inc. (ACAD) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.